Using Plant Virus Based Nanorods to Modulate the Differentiation of Human Bone Marrow Stem Cells
Tobacco mosaic virus (TMV) is a protypical nanorod-shaped bioparticles that has been used as a building block to construct a variety of self-assembled nanomaterials for different biomedical applications, including drug delivery, in vivo imaging, tumor immunotherapy and tissue
engineering. In this work, the roles of TMV and its mutant TMV-RGD1 nanoparticles on the differentiation of human bone marrow stem cells (hBMSCs), an important process in bone regeneration, were carefully investigated. We observed that cells cultured on the TMV-RGD1 nanorods coated substrate
showed significantly higher levels of gene and protein expression of osteo-specific markers osteocalcin (OCN) and bone morphogenetic protein 2 (BMP2). Investigation of alkaline phosphatase (ALP) activity and calcium deposition further confirmed that the TMV-RGD1 substrate could promote the
osteogenesis and induce the mineralization of hBMSCs. On the other hand, the adipogenesis was downregulated on TMV and TMV-RGD1 coated substrates. Taken together, this study demonstrates for the first time the potential of TMV-RGD1 in promoting osteogenic differentiation of hBMSCs which can
lead to future applications in clinical bone engineering.
Keywords: BIONANOPARTICLE; HUMAN BONE MESENCHYMAL STEM CELLS; MULTIVALENCY; NANOTOPOGRAPHY; OSTEOGENIC DIFFERENTIATION
Document Type: Research Article
Publication date: 01 February 2019
- Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content